Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients

被引：0
|
作者：
Jean Claude Alvarez
Pierre Moine
Benjamin Davido
Isabelle Etting
Djillali Annane
Islam Amine Larabi
Nicolas Simon
机构：
[1] Raymond Poincaré Hospital,Department of Pharmacology and Toxicology, Paris
[2] AP-HP,Saclay University (Versailles Saint
[3] Hôpital Raymond Poincaré,Quentin
[4] AP-HP,en
[5] Raymond Poincaré hospital,Yvelines), Inserm U
[6] AP-HP,1173, FHU Sepsis
[7] Raymond Poincaré hospital,Laboratoire de Pharmacologie
[8] AP-HP,Toxicologie, Université de Versailles Saint
[9] Aix-Marseille University,Quentin
来源：
European Journal of Clinical Pharmacology | 2021年 / 77卷
关键词：
Lopinavir; Pharmacokinetics; Covid-19;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：389 / 397
页数：8
相关论文
共 50 条
  • [21] BET 1: LOPINAVIR-RITONAVIR AND COVID-19
    Dolan, Daniel
    Ingham, Jack
    Baombe, Janos
    EMERGENCY MEDICINE JOURNAL, 2020, 37 (07) : 450 - +
  • [22] No Benefit for Lopinavir-Ritonavir in Severe COVID-19
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (20): : 1999 - 1999
  • [23] Lopinavir / ritonavir for COVID-19: A living systematic review
    Verdugo-Paiva, Francisca
    Izcovich, Ariel
    Ragusa, Martin
    Rada, Gabriel
    MEDWAVE, 2020, 20 (06):
  • [24] Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
    Stader, Felix
    Khoo, Saye
    Stoeckle, Marcel
    Back, David
    Hirsch, Hans H.
    Battegay, Manuel
    Marzolini, Catia
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (10) : 3084 - 3086
  • [25] Lopinavir/ritonavir population pharmacokinetics in neonates and infants
    Urien, Saik
    Firtion, Ghislaine
    Anderson, Suzanne T.
    Hirt, Deborah
    Solas, Caroline
    Peytavin, Gilles
    Faye, Albert
    Thuret, Isabelle
    Leprevost, Marthe
    Giraud, Carole
    Lyall, Hermione
    Khoo, Saye
    Blanche, Stephane
    Treluyer, Jean-Marc
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (06) : 956 - 960
  • [26] Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
    Zhu, Zhen
    Lu, Zhaohui
    Xu, Tianmin
    Chen, Cong
    Yang, Gang
    Zha, Tao
    Lu, Jianchun
    Xue, Yuan
    JOURNAL OF INFECTION, 2020, 81 (01) : E21 - E23
  • [27] Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
    Mazan, Paula
    Lesiak, Aleksandra
    Skibinska, Malgorzata
    Kamerys, Juliusz
    Czajkowski, Rafal
    Owczarek, Witold
    Narbutt, Joanna
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2020, 37 (03): : 435 - 437
  • [28] Evaluation of retinotoxicity of COVID-19 treatment: Hydroxychloroquine and lopinavir/ritonavir
    Burgos-Blasco, Barbara
    Guemes-Villahoz, Noemi
    Vidal-Villegas, Beatriz
    Donate-Lopez, Juan
    Garcia-Feijoo, Julian
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (02) : 644 - 646
  • [29] The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment
    Cinarka, Halit
    Gunluoglu, Gulsah
    Cortuk, Mustafa
    Yurt, Sibel
    Kiyik, Murat
    Kosar, Filiz
    Tanriverdi, Elif
    Arslan, Melih Akay
    Baydili, Kursad Nuri
    Koc, Aysu Sinem
    Altin, Sedat
    Cetinkaya, Erdogan
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2021, 51 (04) : 1624 - 1630
  • [30] Population Pharmacokinetics of Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients
    Lopez Aspiroz, Elena
    Santos Buelga, Dolores
    Cabrera Figueroa, Salvador
    Lopez Galera, Rosa Maria
    Ribera Pascuet, Esteban
    Dominguez-Gil Hurle, Alfonso
    Garcia Sanchez, Maria Jose
    THERAPEUTIC DRUG MONITORING, 2011, 33 (05) : 573 - 582
12345